Gugliandolo et al., 2017
What should patients, physicians, insurers, policy makers, and researchers know about GLP-1 cost, access, and safety
And because drugmakers have said they don't sell the active ingredients in their weight-loss shots to compounding pharmacies, it's unclear if the pharmacies are sourcing them from regulated suppliers
Existing Alzheimer's drugs including the recently approved amyloid-targeting antibodies address the disease after it has already begun
When generic versions do become available, they will need to demonstrate bioequivalence to the original brand-name products through clinical trials
Money is also a huge factor: 46% would use these for more than 24 months if there was no co-pay and full insurance coverage, but only 7% would do so on a $100 copay